Fabio Ynoe de Moraes, Associate Professor at Queen’s University, shared a post on LinkedIn about a paper he co-authored with his colleagues published in the Journal of Neuro-Oncology:
“Nomograms for predicting survival of elderly patients with newly diagnosed glioblastoma: a secondary analysis of the CCTG CE.6 trial.
I am pleased to share our newly published study in Journal of Neuro-Oncology, reporting the development and validation of trial-based prognostic nomograms for elderly patients with newly diagnosed glioblastoma, using data from the landmark CCTG CE.6 trial.
Why this matters?
Glioblastoma in older adults is characterized by marked clinical heterogeneity, yet this population is frequently underrepresented in prognostic tools and trial design. Treatment decisions are often made with limited individualized prognostic information.
What we did?
Using data from 562 patients ≥65 years, randomized to radiotherapy (RT) alone or RT plus temozolomide (RT+TMZ), we:
Built multivariable Cox models and translated them into clinically usable nomograms
Performed internal validation with training/testing cohorts.
Stratified patients into distinct risk groups for overall survival (OS) and progression-free survival (PFS).
Key prognostic factors (RT+TMZ cohort, MMSE score, Extent of resection (biopsy-only vs resection), Sex, MGMT promoter status.
These variables generated clear separation of low-, intermediate-, and high-risk groups, with clinically meaningful differences in median OS and PFS, reproduced in validation datasets.
Why it is important?
Provides a pragmatic, trial-derived prognostic tool tailored to elderly GB patients
Supports individualized prognostication at the point of care?
Has potential to inform shared decision-making, treatment intensity discussions, and future trial stratification in this underrepresented population.
This work reflects a broader goal in neuro-oncology: moving beyond one-size-fits-all approaches toward data-driven, patient-centered prognostication, especially where uncertainty is greatest.
Grateful to an outstanding collaborative team and to the Canadian Cancer Trials Group for generating such high-quality clinical trial data.
Nomograms for predicting survival of elderly patients with newly diagnosed glioblastoma: a secondary analysis of the CCTG CE.6 trial, Journal of Neuro-Oncology, 2026.
I welcome discussion on how prognostic tools like this should (and should not) be integrated into routine neuro-oncology practice and clinical trial design.”
Title: Nomograms for predicting survival of elderly patients with newly diagnosed glioblastoma: a secondary analysis of the CCTG CE.6 trial.
Authors: Fabio Y. Moraes, Jonah Isen, James Perry, Norm Laperriere, Alba Brandes, Johan Menten, Claire Phillips, Mike Fay, Ryo Nishikawa, Warren P. Mason, J. Greg Cairncross, Wilson Roa, Keyue Ding, and Chris O’Callaghan.
You can read the full article in Journal of Neuro-Oncology.
More posts featuring Fabio Moraes.